DENTSPLY SIRONA Inc (NASDAQ:XRAY) – William Blair cut their Q3 2018 earnings per share estimates for shares of DENTSPLY SIRONA in a report issued on Wednesday, Zacks Investment Research reports. William Blair analyst J. Kreger now forecasts that the medical instruments supplier will post earnings of $0.69 per share for the quarter, down from their previous forecast of $0.70. William Blair also issued estimates for DENTSPLY SIRONA’s FY2020 earnings at $3.45 EPS.
DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.66 EPS.
Other equities analysts also recently issued reports about the stock. HC Wainwright downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price target on the stock. in a report on Thursday, November 30th. Stifel Nicolaus reissued a “buy” rating on shares of DENTSPLY SIRONA in a report on Thursday, October 19th. TheStreet raised shares of DENTSPLY SIRONA from a “c” rating to a “b-” rating in a report on Friday, November 3rd. Stephens started coverage on shares of DENTSPLY SIRONA in a report on Tuesday, November 28th. They issued an “overweight” rating and a $75.00 price target on the stock. Finally, Robert W. Baird set a $63.00 price objective on DENTSPLY SIRONA and gave the company a “buy” rating in a research note on Thursday, October 19th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $69.15.
DENTSPLY SIRONA (NASDAQ XRAY) opened at $65.79 on Friday. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. The firm has a market cap of $15,110.00, a PE ratio of -18.91, a P/E/G ratio of 2.36 and a beta of 1.31. DENTSPLY SIRONA has a fifty-two week low of $52.53 and a fifty-two week high of $68.98.
The company also recently disclosed a quarterly dividend, which was paid on Friday, January 12th. Investors of record on Friday, December 29th were paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Thursday, December 28th. DENTSPLY SIRONA’s dividend payout ratio is currently -10.06%.
In related news, CFO Nicholas W. Alexos purchased 50,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were purchased at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Brandt sold 6,409 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $68.04, for a total value of $436,068.36. Following the sale, the director now owns 12,073 shares in the company, valued at $821,446.92. The disclosure for this sale can be found here. Insiders own 1.99% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Veritas Asset Management LLP increased its position in shares of DENTSPLY SIRONA by 2.6% in the second quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after purchasing an additional 157,616 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of DENTSPLY SIRONA by 78.7% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock worth $771,000 after purchasing an additional 5,236 shares during the last quarter. Royce & Associates LP increased its position in shares of DENTSPLY SIRONA by 23.4% in the second quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock worth $8,212,000 after purchasing an additional 24,000 shares during the last quarter. Delta Lloyd Asset Management N.V. bought a new position in shares of DENTSPLY SIRONA in the second quarter worth approximately $15,624,000. Finally, Grandfield & Dodd LLC increased its position in shares of DENTSPLY SIRONA by 1.8% in the third quarter. Grandfield & Dodd LLC now owns 236,109 shares of the medical instruments supplier’s stock worth $14,122,000 after purchasing an additional 4,140 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.